29 Vesicular stomatitis virus Indiana strain G protein (VSVind.G) is the most commonly 30 used envelope glycoprotein to pseudotype lentiviral vectors (LV) for experimental and 31 clinical applications. Recently, G proteins derived from other vesiculoviruses (VesG), 32 for example Cocal virus, have been proposed as alternative LV envelopes with 33 possible advantages compared to VSVind.G. Well-characterised antibodies that 34 recognise VesG will be useful for vesiculovirus research, development of G protein-35 containing advanced therapy medicinal products (ATMPs), and deployment of 36 VSVind-based vaccine vectors. Here we show that one commercially available 37 monoclonal antibody, 8G5F11, binds to and neutralises G proteins from three strains 38 of VSV as well as Cocal, and Maraba viruses, whereas the other commercially 39 available monoclonal anti-VSVind.G antibody, IE9F9, binds to and neutralises only 40 VSVind.G. Using a combination of G protein chimeras and site-directed mutations, 41 we mapped the binding epitopes of IE9F9 and 8G5F11 on VSVind.G. IE9F9 binds 42 close to the receptor binding site and competes with soluble low-density lipoprotein 43receptor (LDLR) for binding to VSVind.G, explaining its mechanism of neutralisation.
44In contrast, 8G5F11 binds close to a region known to undergo conformational changes 45 when the G protein moves to its post-fusion structure, and we propose that 8G5F11 46 cross-neutralises VesGs by inhibiting this. 47 IMPORTANCE 48 VSVind.G is currently regarded as the gold-standard envelope to pseudotype lentiviral 49 vectors. However, recently other G proteins derived from vesiculoviruses have been 50 proposed as alternative envelopes. Here, we investigated two anti-VSVind.G 51 monoclonal antibodies for their ability to cross-react with other vesiculovirus G 52 proteins, and identified the epitopes they recognise, and explored the mechanisms 53 behind their neutralisation activity. Understanding how cross-neutralising antibodies 54 interact with other G proteins may be of interest in the context of host-pathogen 55 interaction and co-evolution as well as providing the opportunity to modify the G 56 proteins and improve G protein-containing medicinal products and vaccine vectors.57 58 59The rhabdovirus, vesicular stomatitis virus Indiana stain (VSVind), has been used 60 ubiquitously as a model system to study humoral and cellular immune responses in 61 addition to being a promising virus for oncolytic virotherapy against cancer (1-3).
62Furthermore, its single envelope G protein (VSVind.G) is the most commonly used 63 envelope to pseudotype lentiviral vectors and serves as the gold-standard in many 64 experimental and clinical studies (4-6). Both receptor recognition and membrane 65 fusion of the wild-type virus, as well as the pseudotyped particles, are mediated by this 66 single transmembrane viral glycoprotein that homotrimerises and protrudes from the 67 viral surface (7-9). Recently G proteins derived from other vesiculovirus subfamily 68 members, namely, Cocal, Piry, and ...